Literature DB >> 2408588

Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma.

J Keller, A Kaltenecker, K T Schricker, B Neidhardt, O P Hornstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2408588     DOI： 10.1007/bf00509089

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  10 in total

1.  [Measurement of spontaneous platelet aggregation. Platelet aggregation test III (author's transl)].

Authors:  K Breddin; H Grun; H J Krzywanek; W P Schremmer
Journal:  Klin Wochenschr       Date:  1975-01-15

2.  Prostaglandin E1 therapy for digital ulcers in scleroderma.

Authors:  M Baron; G Skrinskas; M B Urowitz; P N Madras
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

3.  [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].

Authors:  J Keller; A Kaltenecker; K T Schricker; T Krais; A Schönberger; M Gevatter; O P Hornstein
Journal:  Dtsch Med Wochenschr       Date:  1984-09-21       Impact factor: 0.628

4.  Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.

Authors:  P M Dowd; I B Kovacs; C J Bland; J D Kirby
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-01

5.  Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.

Authors:  M F Martin; J E Tooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11

6.  Treatment of severe Raynaud's phenomenon with prostaglandin E1.

Authors:  J A Allen; M J O'Reilly
Journal:  Ir J Med Sci       Date:  1981-06       Impact factor: 1.568

7.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

8.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

9.  Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.

Authors:  A Kahan; S Weber; B Amor; C J Menkes
Journal:  Lancet       Date:  1983-03-05       Impact factor: 79.321

10.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302
  10 in total
  3 in total

1.  Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

Authors:  N J McHugh; M Csuka; H Watson; G Belcher; A Amadi; E F Ring; C M Black; P J Maddison
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

Review 2.  Treatment of systemic sclerosis.

Authors:  T A Medsger
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion.

Authors:  Elisa Tinazzi; Marzia Dolcino; Antonio Puccetti; Antonella Rigo; Ruggero Beri; Maria Teresa Valenti; Roberto Corrocher; Claudio Lunardi
Journal:  Arthritis Res Ther       Date:  2010-07-07       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.